These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1410895)

  • 1. [Orphan drugs: the American model].
    Hanesse B; Tréchot P; Netter P; Royer RJ
    Rev Med Interne; 1992; 13(2):93-6. PubMed ID: 1410895
    [No Abstract]   [Full Text] [Related]  

  • 2. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME
    Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
    Clissold DB
    Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
    Döring JH; Lampert A; Hoffmann GF; Ries M
    PLoS One; 2016; 11(8):e0161660. PubMed ID: 27557111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incentives for drug development--the curious case of colchicine.
    Kesselheim AS; Solomon DH
    N Engl J Med; 2010 Jun; 362(22):2045-7. PubMed ID: 20393164
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA regulatory requirements for investigational new drugs and new drug applications: an update.
    Hoiberg CP; Rapaka RS
    NIDA Res Monogr; 1991; 112():313-25. PubMed ID: 1754003
    [No Abstract]   [Full Text] [Related]  

  • 8. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 9. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 10. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
    Henry V
    J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
    [No Abstract]   [Full Text] [Related]  

  • 11. Orphan products: origins, progress, and prospects.
    Haffner ME
    Annu Rev Pharmacol Toxicol; 1991; 31():603-20. PubMed ID: 2064386
    [No Abstract]   [Full Text] [Related]  

  • 12. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME
    N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
    [No Abstract]   [Full Text] [Related]  

  • 13. The consumer's role in development of orphan drugs.
    Meyers AS
    Prog Clin Biol Res; 1985; 197():51-61. PubMed ID: 3865230
    [No Abstract]   [Full Text] [Related]  

  • 14. A biotechnology view of glycobiology.
    Vapnek D
    Glycobiology; 1990 Sep; 1(1):3-4. PubMed ID: 2136377
    [No Abstract]   [Full Text] [Related]  

  • 15. EPO--one year later. Fighting anemia in the courtroom.
    Riley JB; Pristave RJ
    Nephrol News Issues; 1990 May; 4(5):27. PubMed ID: 2348877
    [No Abstract]   [Full Text] [Related]  

  • 16. [History of the development of US legislation to drugs].
    Utkin OB
    Farmatsiia; 1977; 26(4):78-82. PubMed ID: 332534
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug legislation. Drug companies divided.
    Gershon D
    Nature; 1990 May; 345(6270):6. PubMed ID: 2330052
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulatory aspects of investigational new drugs.
    Arbit HM
    Am J Hosp Pharm; 1978 Jan; 35(1):81-5. PubMed ID: 341700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fifty years of drug amendments revisited: in easy-to-swallow capsule form.
    Kaplan AH
    Food Drug Law J; 1995; 50 Spec():179-96. PubMed ID: 10343042
    [No Abstract]   [Full Text] [Related]  

  • 20. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.